Alkeon Capital Management LLC purchased a new stake in shares of Insmed, Inc. (NASDAQ: INSM) during the second quarter, according to the company in its most recent 13F filing with the Securities and E
California Public Employees Retirement System lessened its position in Insmed, Inc. (NASDAQ: INSM) by 16.3% in the second quarter, according to the company in its most recent filing with the Securitie
Stanley Druckenmiller is a Wall Street legend whose trades are truly worth tracking due to how consistently he has been winning.
BRIDGEWATER, N.J. , Dec. 4, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform
American Century Companies Inc. lowered its stake in shares of Insmed, Inc. (NASDAQ: INSM) by 78.2% during the second quarter, according to the company in its most recent Form 13F filing with the Secu
Insmed Incorporated (INSM) Presents at Evercore 8th Annual Healthcare Conference Transcript
Druckenmiller invests his personal and family's wealth through his fund, the Duquesne Family Office. Druckenmiller is high on biotech stocks, with his top three holdings at the end of the third quarte
Insmed, Inc. (NASDAQ: INSM - Get Free Report) shares hit a new 52-week high during trading on Wednesday. The company traded as high as $209.77 and last traded at $209.02, with a volume of 2093177 shar
Stanley Druckenmiller has been one of the most successful investors, a billionaire with a long record of high returns in global macro investing.
Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Insmed, Inc. (NASDAQ: INSM). In a filing disclosed on November 18th, the Representative disclosed that they had sold bet
Catalyst Funds Management Pty Ltd purchased a new stake in Insmed, Inc. (NASDAQ: INSM) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 47,175 s
INSM climbs after the EU clears Brinsupri as the first approved treatment for NCFB, backed by phase III ASPEN and phase II WILLOW results.
— Non-Cystic Fibrosis Bronchiectasis (NCFB) Is a Serious, Progressive Lung Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI Is a First-in-Disease, First-in-Class DPP1 Inhibitor Tar
Insmed Incorporated ( INSM ) Jefferies London Healthcare Conference 2025 November 18, 2025 3:30 AM EST Company Participants William Lewis - President, CEO & Chairman Conference Call Participants Yuxi
Insmed, Inc. (NASDAQ: INSM - Get Free Report) insider Orlov Nicole Schaeffer sold 30,000 shares of Insmed stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an ave
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE